Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $54.4 million.

  • CG Oncology's Cash from Financing Activities rose 240899.86% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.9 million, marking a year-over-year decrease of 3085.59%. This contributed to the annual value of $628.3 million for FY2024, which is 62218.47% up from last year.
  • Latest data reveals that CG Oncology reported Cash from Financing Activities of $54.4 million as of Q3 2025, which was up 240899.86% from -$296000.0 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Cash from Financing Activities registered a high of $402.7 million during Q1 2024, and its lowest value of -$15.2 million during Q2 2023.
  • Its 3-year average for Cash from Financing Activities is $70.0 million, with a median of $450000.0 in 2025.
  • Per our database at Business Quant, CG Oncology's Cash from Financing Activities skyrocketed by 5273503.27% in 2024 and then plummeted by 84000.0% in 2025.
  • CG Oncology's Cash from Financing Activities (Quarter) stood at -$2.9 million in 2023, then soared by 7814.57% to $223.4 million in 2024, then tumbled by 75.66% to $54.4 million in 2025.
  • Its last three reported values are $54.4 million in Q3 2025, -$296000.0 for Q2 2025, and $450000.0 during Q1 2025.